A Follow-up Study to Evaluate the Safety of ALLO-ASC-CD in ALLO-ASC-CD-101 Clinical Trial

RecruitingOBSERVATIONAL
Enrollment

9

Participants

Timeline

Start Date

November 16, 2016

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Crohn Disease
Interventions
BIOLOGICAL

ALLO-ASC-CD

ALLO-ASC-CD is intravenous infusion containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells are directed to injured tissue, and reduce inflammation. Furthermore their immunomodulatory effects are significant for treating immune-related disease. Finally, ALLO-ASC-CD may provide a new option in treating a crohn's disease. This study is a follow-up study without intervention.

Trial Locations (2)

03080

RECRUITING

Seoul National University Hospital, Seoul

03722

COMPLETED

Severance Hospital, Seoul

All Listed Sponsors
lead

Anterogen Co., Ltd.

INDUSTRY